Background
The availability of image guidance and intensity modulation has led to the increasing use of hypofractionated stereotactic radiotherapy (hSRT) as an alternative to conventionally fractionated radiotherapy or radiosurgery for intracranial meningiomas (ICMs). As the safety and efficacy of this approach is not well characterized, we conducted a systematic review of the literature to assess the clinical outcomes of hSRT in the setting of ICMs.
Methods
A systematic review of Medline and EMBASE databases was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Included studies were retrospective or prospective series that examined an ICM population of ≥10 patients, delivered >1 fraction of photon hSRT (≥2.5 Gy per fraction), and had a median follow-up of ≥2 years. Descriptive statistics were generated for included studies.
Results
Of 1480 initial studies, 14 met eligibility criteria for inclusion, reporting on 630 patients (age range, 18-90) treated for 638 tumors. Primary radiotherapy was delivered in 37% of patients, 36% had radiation following surgery, and surgical details were unavailable for 27%. In 474 tumors assessed for radiologic response, 78% remained stable, 18% decreased in size, and 4% increased in size. Crude local control was 90%-100% as reported in 10 studies. The median late toxicity rate was 10%. The most common significant late toxicities were decreased visual acuity and new cranial neuropathy.
Conclusions
With limited follow-up, the available literature suggests hSRT for ICMs has local control and toxicity profiles comparable to other radiotherapy approaches. Confirmation in larger patient cohorts with a longer duration of follow-up is required.
Leptomeningeal disease (LMD) is the infiltration of tumor cells into the leptomeninges, subarachnoid space and other cerebral spinal fluid (CSF) compartments. It occurs in approximately 5-8% of patients with solid tumors and 5-15% of patients with hematologic malignancies (1). LMD is considered a disease of the "sanctuary" space, where the blood-brain barrier restricts both tumor cells and therapeutic medications (2). While advances in systemic therapies have improved overall disease control, their penetrance into the central nervous system (CNS) is poor given the blood brain barrier, resulting in longer survival in patients with a hyphenate propensity CNS metastases including LMD (3,4). LMD presents as the initial manifestation of metastatic cancer in 5-10% of patients, but more commonly develops in the setting of progressive disease with the median time from the diagnosis
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.